Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects.
Coadjuvant treatments
Intraocular pressure
Melatonin
Supplements
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
19
05
2019
accepted:
19
10
2019
pubmed:
28
10
2019
medline:
8
1
2021
entrez:
26
10
2019
Statut:
ppublish
Résumé
To evaluate the effect of a new nutritional supplement based on melatonin on the intraocular pressure (IOP) in normotensive subjects. A short-term prospective study was designed. Sixty-seven normotensive subjects were recruited. Patients were divided into two groups. The daily group (DG) (n = 18) was instructed to take the supplement between 22:00 and 23:00 (before sleeping) for 3 consecutive days. IOP was measured from 10.00 to 11.00 am the day before treatment and during the 3 days of experiment. The acute group (AG) (n = 49) was instructed to take the supplement after the second measure (11.00) of the second day. IOP was measured 1 h and just before the intake of the supplement and 1 and 2 h after. All measurements in this group were taken 1 day before without any supplement (control) and the day of experiment. The DG group showed a significant decrease in IOP after supplement intake in all days of experiment, from 14.9 ± 3.4 mm Hg to 13.8 ± 2.9 mm Hg after 3 days of experiment (p value < 0.001). For AG, IOP did not change during the control day; however, a reduction of 1 mm Hg was found 2 and 3 h after supplement intake, from 15.7 ± 2.5 mm Hg to 14.7 ± 2.5 mm Hg and 15.1 ± 2.7 mm Hg, respectively, being statistically significant (p value < 0.001). The supplement based on melatonin was able to reduce the IOP in normotensive subjects after 2 h of intake. Moreover, the daily intake showed a reduction in IOP during the 3 days of experiment.
Identifiants
pubmed: 31650354
doi: 10.1007/s10792-019-01199-1
pii: 10.1007/s10792-019-01199-1
doi:
Substances chimiques
Antioxidants
0
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
419-422Références
J Ocul Pharmacol Ther. 2013 Feb;29(1):61-7
pubmed: 23046438
Ophthalmic Physiol Opt. 2015 Mar;35(2):201-5
pubmed: 25600174
Curr Eye Res. 1988 Jul;7(7):649-53
pubmed: 3416618
Clin Exp Ophthalmol. 2012 May-Jun;40(4):341-9
pubmed: 22356435
Auton Neurosci. 2009 May 11;147(1-2):14-9
pubmed: 19176290
Eur J Pharmacol. 2013 Feb 15;701(1-3):213-7
pubmed: 23270715
J Pineal Res. 2003 Jan;34(1):75-8
pubmed: 12485375
Exp Mol Pathol. 2011 Apr;90(2):231-7
pubmed: 21241689
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Acta Ophthalmol (Copenh). 1993 Apr;71(2):185-8
pubmed: 8333263
Optom Vis Sci. 2008 Jan;85(1):61-6
pubmed: 18174841
Pharmacol Ther. 2007 Mar;113(3):507-22
pubmed: 17229466
Molecules. 2010 Jan 20;15(1):442-59
pubmed: 20110903
Acta Neurobiol Exp (Wars). 1994;54 Suppl:57-64
pubmed: 7801793
Anesth Analg. 2009 Apr;108(4):1146-51
pubmed: 19299777